Tag Archives: M&A

Pharma and Biotech Trends 2014

Peter Young examines the fast-moving growth drivers for the two segments and what their 2014 numbers mean for respective M&A and other strategies going forward. The pharmaceutical and biotechnology industries, like all industries, are facing industry-specific changes coupled with disruptive events in the external global environment. The industry business factors include the productivity and cost […]
Posted in Biotech, Deals, Guest Blog, Op-Ed, Strategy | Also tagged , , , , | Leave a comment

Actavis Marches Ahead with Acquisition Spree

Actavis’s agreed purchase of Allergan for around $66 billion will help grow the Dublin-based specialty pharma firm to a $22 billion healthcare company in 2015 — a “dramatic elevation”, given the $8.7 billion revenues it recorded in 2013, reports research and consulting firm GlobalData.
Posted in Deals | Also tagged , , | Leave a comment

J&J Strengthens Infectious Disease Pipeline with Alios Acquisition

Johnson & Johnson completed the acquisition of Alios BioPharma, a privately held clinical-stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash. Alios BioPharma will become part of the infectious diseases therapeutic area of the Janssen Pharmaceutical Companies of Johnson & Johnson. The acquisition […]
Posted in Deals | Also tagged , , | Leave a comment

Is Pfizer Ready for Another Acquisition?

After Pfizer’s aborted acquisition of AstraZeneca, will the drug maker likely approach another company for takeover? This Applied Clinical Trials article discusses some background on Pfizer’s financial history, evaluates its R&D portfolio, and determines whether it is ready for another acquisition attempt. Read more…
Posted in Deals, Strategy | Also tagged , | Leave a comment

Pharma Feels Impact of US Tax Inversion Legislation

The recent termination of AbbVie’s deal to acquire Shire has “jolted the industry out of its reverie” by becoming pharma’s first major casualty of new US tax inversion legislation,  says research and consulting firm GlobalData.
Posted in Deals, Europe, Global, Strategy | Also tagged , , | Leave a comment
  • Categories

  • Meta